BioCentury
ARTICLE | Company News

Celgene, MorphoSys end MOR202 deal

March 27, 2015 12:50 AM UTC

MorphoSys AG (Xetra:MOR; Pink:MPSYF) plummeted EUR 14.05 (20%) to EUR 54.71 after it regained rights from Celgene Corp. (NASDAQ:CELG) to MOR202, a human mAb against CD38 in Phase I/II testing to treat multiple myeloma (MM). The companies mutually agreed to terminate the partnership but did not give reasons.

An ongoing Phase I/IIa trial of MOR202 for relapsed or refractory MM will continue as planned; MorphoSys expects data this year. This half, MorphoSys plans to start new trial cohorts of MOR202 in combination with Celgene's Revlimid lenalidomide and Pomalyst pomalidomide. ...